

REGENERON PHARMACEUTICALS INC

Form 8-K

February 06, 2007

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities and Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 6, 2007 (February 5, 2007)**

**REGENERON PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**New York**

**000-19034**

**133444607**

(State or other jurisdiction of  
incorporation)

(Commission File Number)

**(I.R.S. Employer  
Identification Number)**

**777 Old Saw Mill River Road, Tarrytown, New York**

**10591-6707**

**(Address of principal executive offices)**

**(Zip Code)**

**(914) 347-7000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 1.01 Entry Into a Material Definitive Agreement

Item 9.01 Financial Statements and Exhibits

Exhibit Index

EX-99.A: PRESS RELEASE

---

**Table of Contents**

**Item 1.01 Entry Into a Material Definitive Agreement**

On February 5, 2007, the Company announced that it had entered into a non-exclusive license agreement with AstraZeneca granting AstraZeneca certain rights to use Regeneron's VelocImmune® technology to discover human monoclonal antibodies. Pursuant to the terms of the agreement, AstraZeneca will make a \$20 million upfront payment to Regeneron. AstraZeneca also will make up to five additional annual payments of \$20 million, subject to its ability to terminate the agreement after making the first three additional payments or if the technology does not meet minimum performance criteria. Regeneron is entitled to receive a mid-single-digit royalty on any future sales of antibody products discovered by AstraZeneca using Regeneron's VelocImmune technology.

A copy of the press release announcing the agreement is furnished as Exhibit 99(a) to this Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits

99(a) Press Release of Regeneron Pharmaceuticals, Inc. dated February 5, 2007.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS,  
INC.

Dated: February 6, 2007

By: /s/ Stuart Kolinski  
Stuart Kolinski  
Vice President and General Counsel

**Table of Contents**

**Exhibit Index**

**Number Description**

99(a) Press Release of Regeneron Pharmaceuticals, Inc. dated February 5, 2007.

3